Polymeric nanoparticles for a drug delivery system

Current Drug Metabolism

Volumn 14, Issue 8, 2013, Pages 840-846

  Grottkau, Brian E ^a   Cai, Xiaoxiao ^b   Wang, Jing ^c   Yang, Xingmei ^b   Lin, Yunfeng ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b SICHUAN UNIVERSITY   (China)

^c TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

PHA; PLGA; Polymeric nanoparticles

Indexed keywords

ALBUMIN; ALGINIC ACID; CELLULOSE; CHITIN; GELATIN; MACROGOL; NANOPARTICLE; POLYGLYCOLIC ACID; POLYMER; POLYPEPTIDE; POLYVINYL ALCOHOL; STARCH;

AQUEOUS SOLUTION; ARTICLE; ATOMIC FORCE MICROSCOPY; BIOAVAILABILITY; BIOCOMPATIBILITY; BIODEGRADABILITY; CELL MEMBRANE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; DRUG TARGETING; EMULSION; EVAPORATION; INFRARED SPECTROSCOPY; LASER DIFFRACTION; MOLECULAR STABILITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OPSONIZATION; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; POLYMERIZATION; SCANNING ELECTRON MICROSCOPY; SOLUBILITY; SURFACE PROPERTY; TRANSMISSION ELECTRON MICROSCOPY; ULTRACENTRIFUGATION; X RAY PHOTOELECTRON SPECTROSCOPY;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; POLYMERS;

EID: 84887943025     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920021131400105     Document Type: Article

References (51)

1. Allémann, E.; Gurny, R.; Doelker, E. Preparation of aqueous polymeric nanodispersions by a reversible salting-out process: influence of process parameters on particle size. Int. J. Pharmaceut.,1992, 87(1), 247-253.
2. Langer, R. Drug delivery and targeting. Nature, 1998, 392 (6679 Suppl), 5-10.
3. Muthu, M.S.; Singh, S. Targeted nanomedicines: Effective treatment modalities for cancer, AIDS and brain disorders. Nanomedicine, 2009, 4(1), 105-118.
4. Duncan, R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer, 2006, 6(9), 688-701.
5. Lammers, T.; Subr, V.; Ulbrich, K.; Hennink, W.E.; Storm, G.; Kiessling, F. Polymeric nanomedicines for image-guided drug delivery and tumor targeted combination therapy,. Nano Today, 2010, 5, 197-212.
6. Lammers, T.; Hennink, W.; Storm, G. Tumour-targeted nanomedicines: Principles and practice. Br. J. Cancer, 2008, 99(3), 392-397.
7. Quintanar-Guerrero, D.; Allémann, E.; Fessi, H.; Doelker, E. Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev. Ind. Pharm., 1998, 24, 1113-1128.
8. Reis, C.P. ; Neufeld, R.J. ; Ribeiro, A.J.; Veiga, F. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine, 2006, 2, 8-21.
9. Do, J.H. ; An, J.; Joun, Y.S.; Chung, D.J.; Kim, J.H. Cellularuptake behavior of polymer nanoparticles into consideration of biosafety. Macromol. Res., 2008, 16, 695-703.
10. Peer, D.; Karp, J.M.; Hong, S.; Farokhzad, O.C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotech., 2007, 2(12), 751-760.
11. Dinarvand, R.; Sepehri, N.; Manoochehri, S.; Rouhani, H.; Atyabi, F. Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents. Int.J. Nanomed., 2011, 6, 877-895.
12. Utreja, P.; Jain, S; Tiwary, K. Novel drug delivery systems for sustained and targeted delivery of anti-cancer drugs: Current status and future prospects. Curr. Drug Deliv., 2010, 7(2), 152-161.
13. Shenoy, D.; Little, S.; Langer, R.; Amiji, M. Poly (ethylene oxide)- modified poly (-amino ester) nanoparticles as a pH-sensitive system for tumor targeted delivery of hydrophobic drugs. In vitro evaluations. Mol. Pharm., 2005, 2(5), 357-366.
14. Yang, A.; Yang, L.; Liu, W.; Li, Z.; Xu, H.; Yang, X. Tumor necrosis factor alpha blocking peptide loaded PEG-PLGA nanoparticles: Preparation and in vitro evaluation. Int. J. Pharm., 2007, 331(1), 123-132.
15. Lemoigne, M. Products of dehydration and of polymerization of hydroxybutyric acid. Bull. Soc. Chem. Biol., 1926, 8, 770-782.
16. Taguchi, S.; Doi, Y. Evolution of polyhydroxyalkanoate (PHA) production system by "enzyme evolution": Successful case studies of directed evolution. Macromol. Biosci., 2004, 4, 145-156.
17. Valappil, S.P.; Misra, S.K.; Boccaccini, A.R.; Roy, I. Biomedical applications of polyhydroxyalkanoates, an overview of animal testing and in vivo responses. Expert Rev. Med. Devices, 2006, 3, 853-868.
18. Wu, Q.; Wang, Y.; Chen, G.Q. Medical application of microbial biopolyesters polyhydroxyalkanoates. Artif. Cells Blood Substit. Biotechnol., 2009, 37, 1-12.
19. Chen, G.Q.; Wu, Q. The application of polyhydroxyalkanoates as tissue engineering materials. Biomaterials, 2005, 26, 6565-6578.
20. Xiong, Y.C.; Yao, Y.C.; Zhan, X.Y.; Chen, G.Q. Application of polyhydroxyalkanoates nanoparticles as intracellular sustained drug-release vectors. J. Biomater. Sci. Polym. Ed., 2010, 21, 127-140.
21. Athanasiou, K.A.; Niederauer, G.G.; Agrawal, C. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials, 1996, 17(2), 93-102.
22. Stevanovic, M.; Uskokovic, D. Poly(lactide-co-glycolide)-based micro and nanoparticles for the controlled drug delivery of vitamins. Curr. Nanosci., 2009, 5(1), 1-14.
23. Panyam, J.; V. Labhasetwar, Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev., 2003, 55(3), 329-347.
24. Nafee, N.; Taetz, S. Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: Effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomed. Nanotechnol. Biol. Med., 2007, 3, 173-183.
25. Parveen, S.; Sahoo, S.K. Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery. Eur. J. Pharmacol., 2011, 670, 372-383.
26. Anderson, J.M.; Shive, M.S. Biodegradation and biocompatibility of PLA and PLGA microspheres, Adv. Drug Deliv. Rev., 1997, 28, 5-24.
27. Kang, F.; Singh, J. Conformational stability of a model protein (bovine serum albumin) during primary emulsification process of PLGA microspheres synthesis. Int. J. Pharmaceut., 2003, 260, 149-156.
28. Guo, J.; Gao, X. Aptamer-functionalized PEGePLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials, 2011, 32, 8010-8020.
29. Jackson, J.K.; Hung, T. The characterization of paclitaxel-loaded microspheres manufactured from blends of poly(lactic-co-glycolic acid) (PLGA) and low molecular weight diblock copolymers. Int. J. Pharmaceut., 2007, 342, 6-17.
30. Fonseca, C. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J. Control. Release, 2002, 83, 273-286.
31. Perugini, P. ; Genta, I. PLGA microspheres for oral osteopenia treatment: preliminary "in vitro"/"in vivo" evaluation. Int. J. Pharmaceut., 2003, 256, 153-160.
32. Zhou, J. Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Biomaterials, 2012, 33, 583-591.
33. Semete, B.; Booysen, L. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomed. Nanotechnol. Biol. Med., 2010, 6, 662-671.
34. Misra, S.K.; Valappil, S.P.; Roy, I.; Boccaccini, A.R. Polyhydroxyalkanoate (PHA)/inorganic phase composites for tissue engineering applications. Biomacromolecules, 2006, 7, 2249-2258.
35. Köse, G.T.; Ber, S.; Korkusuk, F.; Hasirci, V. Poly(3- hydroxybutyric acid-co-3-hydroxyvaleric acid) based tissue engineering matrices. J. Mater. Sci. Mater. Med., 2003, 14, 121- 126.
36. Madison, L.L.; Huisman, G.W. Metabolic engineering of poly(3- hydroxyalkanoates): from DNA to plastic. Microbiol. Mol. Biol. Rev., 1999, 63, 21-53.
37. Yao, Y.C.; Y.C. Zhan, Y.C.; Zhang, J.; Zou, X.H.; Wang, Z.H.; Xiong, Y.C.; Chen, J.; Chen, G.Q. A specific drug targeting system based on polyhydroxyalkanoate granule binding protein PhaP fused with targeted cell ligands. Biomaterials, 2008, 29, 4823-4830.
38. Lu, X.Y.; Ciraolo, E.; Stefenia, R.; Chen, G.Q.; Zhang, Y.L.; Hirsch, E. Sustained release of PI3K inhibitor from PHA nanoparticles and in vitro growth inhibition of cancer cell lines. Appl. Microbiol. Biotechnol., 2011, 89, 1423-1433.
39. Gogolewski, S.; Jovanovic, M.; Perren, S.M.; Dillon, J.G.; Hughes, M.K. Tissue response and in vivo degradation of selected polyhydroxyacids: Polylactides (PLA), poly(3-hydroxybutyrate) (PHB), and poly(3-hydroxybutyrate- co-3-hydroxyvalerate) (PHB/VA). Biomed. Mater. Res., 1993, 27(9), 1135-1148.
40. Koosha, F.; Muller, R.H.; Davis, S.S. Polyhydroxybutyrate as a drug carrier. Crit. Rev. Ther. Drug Carrier Syst., 1989, 6, 117-130.
41. Peng, Q.; Zhang, Z.-R.; Gong, T.; Chen, G.-Q.; Sun, X. A rapidacting, long-acting insulin formulation based on a phospholipids complex loaded PHBHHx nanoparticles. Biomaterials, 2011, 33(5), 1583-1588.
42. Shah, M.; Naseer, M.I.; Choi, M.H.; Kim, M.O; Yoon, S.C. Amphiphilic PHA-mPEG copolymeric nanocontainers for drug delivery: preparation, characterization and in vitro evaluation. Int. J. Pharmaceut., 2010, 400 (1-2), 165-175.
43. Madison, L.L.; Huisman, G.W. Metabolic engineering of poly(3- hydroxyalkanoates): from DNA to plastic. Microbiol. Mol. Biol. Rev., 1999, 63, 21-53.
44. Duvvuri, S.; Gaurav Janoria, K.; Mitra, A.K. Effect of polymer blending on the release of ganciclovir from PLGA microspheres. Pharm. Res., 2006 , 23(1), 215-23.
45. Chena, S.; Pieperb, R.; Webster, Dean C.; Singh, J. Triblock copolymers: synthesis, characterization, and delivery of a model protein. Int. J. Pharmaceut., 2005, 288, (2), 207-218.
46. Mora-Huertas, C.E.; Fessi, H.; Elaissari, A. Polymer-based nanocapsules for drug delivery. Int. J. Pharm., 2010, 385, 113-142.
47. Giavaresi, G.; Tschon, M.; Borsari, V.; Daly, J.H.; Liggat, J.J; Fini, M.; Bonazzi, V.; Nicolini, A. A. Carpi, M. Morra, C. Cassinelli, R. Giardino, New polymers for drug delivery systems in orthopaedics: in vivo biocompatibility evaluation. Biomed. Pharmacother., 2004, 58, 411-417.
48. Pouton, C.W.; Akhtar,S. Biosynthetic polyhydroxyalkanoates and their potential in drug delivery. Adv. Drug Deliv. Rev., 1996, 18(2), 133-162.
49. Bazzo, G.C.; Caetano, D.B.; Boch, M.L.T.; Mosca, M.; Branco, L.C.; Zétola, M.; Pereira, E.M.; Pezzini, B.R. Enhancement of felodipine dissolution rate through its incorporation into eudragit® E-PHB polymeric microparticles: In vitro characterization and investigation of absorption in rats. J. Pharm. Sci., 2012, 101(4), 1518-1523.
50. Wieczorek, R.; Pries, A.; Steinbuchel, A.; Mayer, F. Analysis of a 24-kilodalton protein associated with the polyhydroxyalkanoic acid granules in Alcaligenes eutrophus. J. Bacteriol., 1995, 177, 2425-2435.
51. Potter, M.; Madkour, M.H.; Mayer, F.; Steinbuchel, A. Regulation of phasin expression and polyhydroxyalkanoate (PHA) granule formation in Ralstonia eutropha H16. Microbiology, 2002, 148, 2413-2426.